Pauza Charles David 4

What Happened Charles David Pauza, Chief Science Officer — Virology at Traws Pharma (TRAW) — was granted a derivative award on 2026-03-08 covering 118,367 shares. The Form 4 reports the acquisition as A (award/grant) at $0.00 (derivative). The award represents stock options issued under the company’s 2021 Incentive Compensation Plan.

Key Details

• Transaction date: 2026-03-08; Form 4 filed: 2026-03-10 (timely).
• Reported amount: 118,367 shares (derivative award) shown at $0.00 on the Form 4.
• Vesting: Award will vest 100% on the first anniversary of the grant date (per footnote).
• Plan/approval: Options awarded under the Issuer’s 2021 Incentive Compensation Plan; award approved by the compensation committee comprised of independent directors.
• Shares owned after transaction: Not specified in the provided summary of the filing.

Context This was an option grant (a compensation award), not an open‑market purchase or sale. The grant does not represent immediately tradable shares — it vests in one year and would typically require exercise (and possible payment of an exercise price) before shares are acquired; the Form 4 reports the award as a derivative with $0.00 shown and does not disclose additional exercise-price details here. Such grants are routine executive compensation and do not by themselves indicate a buy or sell signal.